IRCT20171105037262N4 IRCT 2020-06-18 Bagheiat-allah University of Medical Sciences Adalimumab effect on COVID-19 Evaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19 2020-04-29 anticipated 100 Complete https://irct.ir/trial/47696 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: After specifying the sample size, blocks of size 4 consisting of A and B letters are formed (6 blocks). Then, each of the blocks is numbered 1 to 6 and based on the selected numbers from random numbers table, we form a sequence of blocks, in which the letters A and B are located, and then randomly one of the letters are considered as the drug group and the other letter as the control group. This method is referred to as "Permuted Blocked Randomization", Blinding description: Since this is a single-blind study, our blindness would be single-blinded and only patients participating in this study are blind. 3 COVID-19. Intervention 1: Intervention group: 50 patients with COVID-19 who receive routine antiviral treatment and chloroquine, have more than normal levels of TNF-α, and are at risk of critical disease statement (1-respiratory failure that needs mechanical ventilation, 2-shock, 3-any organ failure, 4-need to be admitted in ICU) will receive subcutaneous injection of anti-TNF-α (adalimumab), 40 mg, in periumbilical region of the abdomen. According to altered clinical and laboratory findings, mentioned dose can be repeated. Intervention 2: Control group: 50 matched patients receiving equal antiviral treatment and chloroquine. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information